312 related articles for article (PubMed ID: 33470080)
1. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Auchynka V; Kumar AMV; Hurevich H; Sereda Y; Solodovnikova V; Katovich D; Setkina S; Yedilbayev A; Skrahin A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470081
[TBL] [Abstract][Full Text] [Related]
3. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
[TBL] [Abstract][Full Text] [Related]
5. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
6. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB
Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021
[TBL] [Abstract][Full Text] [Related]
7. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
9. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
10. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
Maretbayeva SM; Rakisheva AS; Adenov MM; Yeraliyeva LT; Algozhin YZ; Stambekova AT; Berikova EA; Yedilbayev A; Rich ML; Seung KJ; Issayeva AM
Int J Infect Dis; 2021 Dec; 113 Suppl 1():S91-S95. PubMed ID: 33823277
[TBL] [Abstract][Full Text] [Related]
11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
[TBL] [Abstract][Full Text] [Related]
13. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
14. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
[TBL] [Abstract][Full Text] [Related]
15. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Dhakulkar S; Das M; Sutar N; Oswal V; Shah D; Ravi S; Vengurlekar D; Chavan V; Rebello L; Meneguim AC; Iyer A; Mansoor H; Kalon S; Acharya S; Ferlazzo G; Isaakidis P; Thakur HP
PLoS One; 2021; 16(2):e0246639. PubMed ID: 33600431
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
[TBL] [Abstract][Full Text] [Related]
20. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C; Khan U; Bastard M; Lachenal N; Coutisson S; Osso E; Ahmed S; Khan P; Franke MF; Rich ML; Varaine F; Melikyan N; Seung KJ; Adenov M; Adnan S; Danielyan N; Islam S; Janmohamed A; Karakozian H; Kamene Kimenye M; Kirakosyan O; Kholikulov B; Krisnanda A; Kumsa A; Leblanc G; Lecca L; Nkuebe M; Mamsa S; Padayachee S; Thit P; Mitnick CD; Huerga H
Clin Infect Dis; 2022 Sep; 75(6):1006-1013. PubMed ID: 35028659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
